About the Company
Expanding immune system stimulation to revolutionize vaccines… That is Inovio’s (NYSE MKT: INO) quest. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease. At Inovio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.
PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging Infectious Diseases,”...
Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this vaccine...
Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
PLYMOUTH MEETING, Pa., June 07, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract...
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2 immuno-oncology trial will evaluate Genentech’s atezolizumab...